Search results
Results from the WOW.Com Content Network
This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Extended cycle use of COCPs may also be called menstrual suppression, [2] although other hormonal medications or medication delivery systems (hormonal intrauterine devices—IUDs) may also be used to suppress menses. Any brand of combined oral contraceptive pills can be used in an extended or continuous manner by simply discarding the placebo ...
Samidorphan (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name) is an opioid antagonist that in the form of olanzapine/samidorphan (sold as Lybalvi) is used in the treatment of schizophrenia and bipolar disorder. [1] [3] [4] Samidorphan reduces the weight gain associated with olanzapine. [5] [6] Samidorphan ...
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact ...
Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). [7] It is used in the treatment of various conditions, most notably obsessive–compulsive disorder but also many other disorders, including hyperacusis, panic disorder, major depressive disorder, trichotillomania, [8] body dysmorphic disorder [9] [10] [11] and chronic pain. [7]
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release. The ...
It’s FDA-approved to help people with type 2 diabetes manage their blood sugar levels. It’s also often prescribed off-label for weight loss. It’s also often prescribed off-label for weight loss.
Vilazodone was approved for medical use in the United States in 2011 [1] and in Canada in 2018. [8] In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions. [9] The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics. [10]